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Objective: To evaluate the feasibility of fertility-sparing surgery in treating advanced-stage borderline
ovarian tumors (BOTs).
Materials and methods: The databases of PubMed, Cochrane Library, EMbase, Web of Science, Chinese
National Knowledge Infrastructure (CNKI), Weipu (Chinese), and Wanfang (Chinese) were searched using
the keywords “advanced-stage borderline ovarian tumors”, “fertility-sparing surgery”, “conservative
surgery”, and “borderline ovarian tumor” to collect the clinical controlled trails (CCTs) regarding fertility-
sparing surgery for the treatment of advanced-stage BOT. The references of those CCTs were also
searched manually. Data extraction and quality assessment were done using Review manager Version 5.1
and R software Version 2.11.1.
Results: Four studies involving 74 patients were included. The results of meta-analysis showed that: (1)
compared with radical surgery, the recurrence of the fertility-sparing surgery during the follow time is
higher with signiﬁcant difference [odds ratio (OR)¼ 3.87, 95% conﬁdence interval (CI) (1.20,12.44),
p¼ 0.02]; (2) the difference of survival rate between the two groups was not signiﬁcant [5-year survival:
OR¼ 0.85, 95%CI (0.03, 23.82), p¼ 0.92; 7-year survival: OR¼ 0.80, 95%CI (0.08, 8.41), p¼ 0.85]; and (3)
concerning fertility results in fertility-sparing surgery, 18 patients tried to become pregnant, 15 preg-
nancies were achieved in the 11 patients, 11 full-term deliveries.
Conclusion: The rate of ovarian recurrence in patients who underwent conservative treatment was
higher than in patients with radical treatment, but it did not affect patient survival; fertility-sparing
surgery could be induced to preserve the fertility potential of young patients.
Copyright © 2016, Taiwan Association of Obstetrics & Gynecology. Published by Elsevier Taiwan LLC. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).Introduction
Borderline ovarian tumors (BOTs), ﬁrst described in 1929 [1],
constitute approximately 10e15% of all epithelial ovarian malig-
nancies. BOTs, which are recognized as a separate diagnostic cate-
gory of epithelial ovarian tumors, are characterized pathologically
by features of malignant tumors, including cellular proliferation,
stratiﬁcation of the epithelial lining of the papillae, nuclear atypia,
and mitotic activity, but without destructive stromal invasion [2].
Clinically, BOTs are detected at earlier stages and younger age at
diagnosis, have more indolent behavior, longer survival, and later
recurrence compared with invasive ovarian cancer [3]. Althoughecology, Renmin Hospital of
hina.
bstetrics & Gynecology. Published bthe majority of BOTs are found in the early stages, approximately
20% still present in advanced stages (Stages IIeIV) at the time of
diagnosis [4]. Stage II or Stage III was deﬁned as the presence of a
BOT in addition to pelvic (Stage II) and/or abdominal (Stage III)
peritoneal implants. Surgery is the most important treatment for
BOTs, including fertility-sparing surgery, radical surgery, and
complete surgical staging. Fertility-sparing surgery was deﬁned as
a procedure with preservation of the uterus and at least part of one
ovary, which include four types: unilateral adnexectomy (UA),
UAþ contralateral cystectomy (UAþCC), unilateral cystectomy
(UC), and bilateral cystectomy (BC). Fertility-sparing surgery for
early-stage BOTs is accepted as a valuable alternative in a number of
young patients who want to preserve their fertility [3,5]. In recent
years, very few studies reported the fertility outcome of conser-
vative management in patients with advanced-stage BOTs. How-
ever, the prognosis of patients with invasive implants is much
poorer [6], such patients with conservative surgery are not usuallyy Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
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is still unclear in young patients with advanced-stage disease [7].
This study aimed to evaluate the safety and effectiveness of
fertility-sparing surgery in treating advanced-stage BOTs.
Materials and methods
Search strategy and selection criteria
We sought data from published articles which were compared
with the clinical results between conservative surgery and radical
surgery byelectric andmanual searching.We followed the guideline
of MOOSE [8] (Meta-analysis of Observational Studies in Epidemi-
ology) and the recommendations of Cochrane handbook Version
5.1.0 [9] to systematically conduct and report this meta-analysis.
We searched from May 2001 to April 2014 using electronic da-
tabases. Electronic database searching included PubMed, Cochar-
ane Library, EMbase, Web of Science, Chinese National Knowledge
Infrastructure (CNKI), VIP (Chinese), and Wanfang (Chinese). The
keywords used were “advanced-stage borderline ovarian tumors”,
“fertility-sparing surgery”, “conservative surgery”, and “borderline
ovarian tumor”. Over the same period, we also manually searched
using the references cited in the acquired articles. No language
restrictions were made. In addition, we searched related
magazines.
The eligibility criteria applied was the following: (1) conﬁrmed
by clinical pathology with advanced BOT; (2) did not receive pre-
operative chemotherapy; (3) compared conservative surgery with
radical surgery; (4) report on at least one of the outcome measures
which include reproduction outcomes, recurrent rate, and survival
rate. Articles were excluded from the analysis if: (1) conﬁrmed by
pathology with the other ovarian tumor; (2) the clear follow-up
results were not mentioned; (3) the outcomes were not clearly
reported; (4) they were without a control group; (5) it was
impossible to extract data from the study; and (6) they are repeat
published literature.
Study selection
Two reviewers reviewed all potential studies and accessed them
using a three-step processes. Firstly, they independently reviewed
the titles and abstracts of all potential studies to exclude duplica-
tions. Secondly, they examined the studies by title, abstract, and full
text to assess whether the studies ought to be included or excluded.
Thirdly, they accessed the studies using qualitative synthesis. When
the judgments of two reviewers had differences, a further discus-
sion would be presented to solve the problem.
Quality assessment
We assessed the quality of individual studies using the New-
castleeOttawa Scale. Speciﬁcally, the NewcastleeOttawa Scale in
the methods indicates cases independently validated, representa-
tiveness of the cases, selection of controls, deﬁnition of controls,
comparability, ascertainment of exposure by blinded interview or
record, same method of ascertainment used for cases and controls,
and nonresponse rate the same for cases and controls.
Statistical analysis
Analysis was performed using the statistical software Review
Manager Version 5.1 and R software Version 2.11.1 [10]. Heteroge-
neity was evaluated using the c2 test, p 0.05 was considered
signiﬁcant for heterogeneity. If heterogeneitywith p> 0.05, I2< 50%
was present, the ﬁxed effects model was used. If heterogeneity withp 0.05, I2 50% was present, the random effects model was used.
If heterogeneity with p 0.05, I2 50% was shown, a sensitivity
analysis was performed. The sensitivity analysis was conducted
using R software (Version 2.11.1, package meta) [10].
Dichotomous variables were analyzed using odds ratio (OR)
and 95% conﬁdence interval (CI), and continuous variables were
represented using mean difference and 95% CI. When there were
no events in one group, it would be solved by adding 0.5 to each
cell of the 2 2 table [11]. In addition, if there were no events for
both groups, the study was excluded. If the clinical trial data
could not be incorporated into the analysis, the descriptive
analysis was used. Publication bias was represented by funnel
plots and was further assessed using R software (Version 2.11.1,
package meta) [10].
Results
Search results
A total of 48 relevant studies were identiﬁed for initial review.
Twenty original studies were excluded for duplicates. By reviewing
the titles and abstracts [4,7,12e37], 14 of the original studies were
excluded for not having a control group [4,7,12e23]. Then the full
text of the remaining studies were reviewed, seven studies were
excluded because they did not provide sufﬁcient information
[24e30], and three articles were eliminated because the criteria of
case selectionwere not the same [31e33]. Finally, four studies were
included in the analysis (Figure 1) [34e37].
The characteristics of the included studies are shown in Table 1,
and ratings of study quality for each of the NewcastleeOttawa
criteria [38] are presented in Table 2. Overall, four relevant studies
were identiﬁed. The total analysis population was 74, 35 of which
were in fertility-sparing surgery, and 39 in radical surgery. In
summary, the quality of each publication's score was high. A higher
score represented a better methodological quality.
Meta-analysis
All of the four studies reported recurrence rates. There was no
evidence of heterogeneity among these studies (p¼ 0.57, I2¼ 0%).
Therefore, ﬁxed effects model was used. Figure 2 shows the forest
plots for recurrence rate. The results showed that fertility-sparing
surgery achieved signiﬁcantly higher recurrence rate [OR¼ 5.58,
95%CI (1.66, 18.78), p¼ 0.005].
Three studies [34e36] reported survival rate. There was no ev-
idence of heterogeneity among these studies (p¼ 0.96, I2¼ 0%).
Fixed effects model was used. Figure 3 shows the forest plots for 5-
year survival rate, and Figure 4 for 7-year survival rate. The results
were shown without signiﬁcant difference [5-year survival:
OR¼ 0.85, 95%CI (0.03, 23.82), p¼ 0.92; 7-year survival: OR¼ 0.80,
95%CI (0.08, 8.41), p¼ 0.85].
Three studies [35e37] reported reproductive outcome. Song
et al [35] reported that four patients had attempted to conceive,
four healthy term babies had been born without congenital
anomalies, and one woman was in the second trimester of preg-
nancy. Kane et al [36] presented that seven pregnancies were
achieved in the ﬁve patientsdﬁve full-term deliveries, one ectopic
pregnancy, and one spontaneous abortion. Defﬁeux et al [37] re-
ported ﬁve patients tried to become pregnant, and three sponta-
neous pregnancies were observed in two patients.
Sensitivity analysis and subgroup analysis
A sensitivity analysis was performed using the random effects
model and inverse variance method to detect the stability of these
48 relev ant studies were identified 
through database searching
20 of the original studies were excluded by duplicates
28 studies reviewed 
the title and abstract
14 studies remov ed for not hav ing a control group
14 studies reviewed the full text
10 studies were excluded 
Did not hav e sufficient information (n =7)
The criteria of case selection were not the same(n =3)
4 studies were included in the analysis
Figure 1. Flow diagram of search strategy.
Table 1
Characteristics of included studies.
Study Age (y), mean Cases Follow up (mo) Histological type (cases) Outcomes
Conservative group Radical group Conservative group Radical group Conservative group Radical group
Vigano et al [34] 36 49 10 12 91 S¼ 10
N¼ 0
S¼ 12
N¼ 0
A;B;C
Song et al [35] 32 48 5 20 71.4 S¼ 4
N¼ 1
S¼ 16
N¼ 4
A;B;C;D
Kane et al [36] 25.9 45.8 13 5 38 S¼ 10
N¼ 0
S¼ 10
N¼ 0
A;B;C;D
Defﬁeux et al [37] 22.3 50.5 7 2 35 S¼ 10
N¼ 0
S¼ 10
N¼ 0
A;D
A¼ recurrent rate; B¼ 5-year survival rate; C¼ 7-year survival rate; D¼ reproduction outcomes; N¼mucinous tumor; S¼ serous tumor.
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obtained (Table 3). The sensitivity analysis showed that the results
were relatively stable.
As BOTs could be divided into six categories according to their
histopathology, but were mainly divided into serous and mucinous
types, we, therefore, conducted subgroup analysis for serous or
mucinous categories. To stay in line with previous analyses, the
subgroup analyses were also performed for recurrence rate, 5-year
survival, and 7-year survival (Figures 5e7).The results were similar
to previous analyses. Especially, for the serous type of borderline
tumor, the results showed that fertility-sparing surgery achieved
signiﬁcantly higher recurrence rate but without signiﬁcantdifference in the 5-year survival rate or 7-year survival rate. For the
mucinous borderline tumor, the results remain the same.Discussion
This study performed a meta-analysis to evaluate the feasibility
of fertility-sparing surgery in treating advanced-stage BOTs. Only
four studies met the inclusion and exclusion criteria and all were of
small to a small size. However, each publication represented a
better methodological quality than other studies. In addition, the
sensitivity analysis indicated that the results were relatively stable.
Table 2
Assessment of study quality.
Studies Quality indicators from NewcastleeOttawa Scalea
1 2 3 4 5 6 7 8
Vigano et al [34] Yes Yes No Yes Yes Yes Yes Yes
Song et al [35] Yes Yes No Yes Yes Yes Yes No
Kane et al [36] Yes Yes No Yes Yes Yes Yes No
Defﬁeux et al [37] Yes Yes No Yes Yes Yes Yes Yes
a For the studies: 1, indicates cases independently validated; 2, representative-
ness of the cases; 3, community controls; 4, controls that have radical surgery; 5,
comparability, 6, ascertainment of exposure by blinded interview or record; 7, same
method of ascertainment used for cases and controls; 8, nonresponse rate the same
for cases and controls.
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that whether it is serous or mucinous tumor type, the rate of
recurrence in patients who have conservative treatment is higher
than in those who have radical treatment. However, such man-
agement does not affect survival. There have been many studies
indicating their excellent long-term prognosis [39]. The 10-year
survival rate is: 99% for Stage I, 98% for Stage II, 96% for Stage III,
and 77% for Stage IV [4,40]. Laurent et al [13] reported cases in
patients who were treated conservatively with serous BOT withStudy or subgroup
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Figure 3. Forest plot forstromal microinvasion but without micropapillary pattern, most
patients who had recurrence of disease following conservative
treatment had borderline tumor, and such recurrence can be easily
cured using a surgical approach. Camatte et al [12] reported 17
cases in patients with advanced-stage disease: two patients
relapsed, no patient died. Song and Kong [41] also reported similar
results. In the recent paper by Uzan et al [7] including 11 BOTs with
invasive implants, eight relapsed, two of whom had invasive car-
cinoma. According to the literature, the most important prognostic
factor of patients with advanced-stage BOT is the histologic char-
acteristics of the implants (noninvasive or invasive), and the
prognosis of patients with invasive implants is much poorer.
Therefore, the higher risk of relapse can be accepted because of the
good prognosis and the role of a second surgery. Fertility-sparing
surgery in the case of a patient with advanced-stage BOT should
be considered if she does not have tumors with invasive implants.
In our series, the reproductive outcomes were less reported. Our
study reports 15 pregnancies in 11 patients treated conservatively,
and 13 healthy term babies were born. Our results conﬁrm that
fertility outcome is good, following conservative treatment of
advanced stage BOT. In the recent series by Uzan et al [7], the
pregnancy rate was 57.1% according to long-term follow up.
Camatte et al [12] also reported similar results. These resultsM-H, Fixed, 95% CI
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Figure 4. Forest plot for 7-year survival rate.
Table 3
Sensitivity analysis with alternating analytical models.
Fixed effects model Random effects model
OR 95%CI p I2 (%) OR 95%CI p I2 (%)
Recurrence rate 5.58 (1.66, 18.78) 0.005 0 5.34 (1.42, 20.06) 0.01 0
5-year survival 0.85 (0.03, 28.82) 0.92 0 0.85 (0.03, 28.82) 0.92 0
7-year survival 0.80 (0.08, 8.41) 0.85 0 0.80 (0.08, 8.53) 0.85 0
CI¼ conﬁdence interval; OR¼ odds ratio.
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Figure 5. Subgroup forest plot of recurrence rate.
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Figure 6. Subgroup forest plot of 5-year survival.
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Figure 7. Subgroup forest plot of 7-year survival.
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even if the patient had an advanced-stage BOT, are very promising.
This study has several limitations: (1) only four studies met the
inclusion criteria, all of which were of small size. It was greatly
underpowered to draw any conclusions. Our results showed that
fertility-sparing surgery in the case of a patient with advanced-
stage BOT should be considered, but these results had not been
demonstrated for a large enough number of; (2) all included studies
were of retrospective design, therefore possibly introducing some
degree of bias; (3) all the included studies were published in En-
glish, the present meta-analysis was limited by language bias.
Moreover, we did not search for unpublished studies, and therefore
the study might be limited by publication bias; (4) there were only
four outcomes, such as recurrence, 5-year survival, 7-year survival
and pregnancy, reported in our study, which is not enough to
determine the feasibility. Therefore, more outcomes are needed for
further study; and (5) the conclusion we made is not signiﬁcantly
different from those of previous articles, it indicates the research
progress of BOT is rather complex, and more research is needed.
Conclusion
In conclusion, fertility-sparing surgery achieves a higher recur-
rence rate. However, it does not affect survival, and reproductive
outcomes are promising. However, more well-designed clinical
trials are needed to determine the feasibility of fertility-sparing
surgery in treating advanced-stage BOT with different patholog-
ical types.
Conﬂicts of interest
All authors have no conﬂicts of interest to declare.
References
[1] Taylor HC. Malignant and semimalignant tumors of the ovary. J Surg Gynecol
Obstet 1929;48:204e30.
[2] Acs G. Serous and mucinous borderline (low malignant potential) tumors of
the ovary. Am J Clin Pathol 2005;123(Suppl):S13e57.
[3] Tinelli R, Tinelli A, Tinelli FG, Cicinelli E, Malvasi A. Conservative surgery for
borderline ovarian tumors: a review. Gynecol Oncol 2006;100(1):185e91.
[4] Zanetta G, Rota S, Chiari S, Bonazzi C, Bratina G, Mangioni C. Behavior of
borderline tumors with particular interest to persistence, recurrence, and
progression to invasive carcinoma: a prospective study. J Clin Oncol
2001;19(10):2658e64.
[5] Kim JH, Kim TJ, Park YG, Lee CW, Song MJ, Lee KH, et al. Clinical analysis of
intra-operative frozen section proven borderline tumors of the ovary. J
Gynecol Oncol 2009;20(3):176e80.
[6] Park JY, Kim DY, Kim JH, Kim YM, Kim KR, Kim YT, et al. Micropapillary pattern
in serous borderline ovarian tumors: does it matter? Gynecol Oncology
2011;123(3):511e6.
[7] Uzan C, Kane A, Rey A, Gouy S, Duvillard P, Morice P. Outcomes after con-
servative treatment of advanced-stage serous borderline tumors of the ovary.
Ann Oncol 2010;21(1):55e60.
[8] Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-
analysis of observational studies in epidemiology: a proposal for reporting.
Meta-analysis of Observational Studies in Epidemiology (MOOSE) group.
JAMA 2000;283:2008e12.
[9] Higgins JPT, Green S, editors. Cochrane Handbook for Systematic Reviews of
Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collabora-
tion; 2011. Available from, www.cochranehandbook.org.
[10] R Development Core Team R. A language and environment for statistical
computing. Vienna, Austria: R Foundation for Statistical Computing; 2010.
http://www.R-project.org.
[11] Mantel N, Haenszel W. Statistical aspects of the analysis of data from retro-
spective studies of disease. J Natl Cancer Inst 1959;22(4):719e48.
[12] Camatte S, Morice P, Pautier P, Atallah D, Duvillard P, Castaigne D. Fertility
results after conservative treatment of advanced stage serous borderline
tumour of the ovary. BJOG 2002;109(4):376e80.
[13] Laurent I, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P. Results after con-
servative treatment of serous borderline tumours of the ovary with stromal
microinvasion but without micropapillary pattern. BJOG 2009;116(6):860e2.[14] Laurent I, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P. Results after
conservative treatment of serous borderline tumors of the ovary with a
micropapillary pattern. Ann Surg Oncol 2008;15(12):3561e6.
[15] Romagnolo C, Gadducci A, Sartori E, Zola P, Maqqino T. Management of
borderline ovarian tumors: results of an Italian multicenter study. Gynecol
Oncol 2006;101(2):255e60.
[16] Maneo A, Vignali M, Chiari S, Colombo A, Mangioni C, Landoni F. Are
borderline tumors of the ovary safely treated by laparoscopy? Gynecol Oncol
2004;94(2):387e92.
[17] Fauvet R, Boccara J, Dufournet C, Poncelet C, Darai E. Laparoscopic manage-
ment of borderline ovarian tumors: results of a French multicenter study. Ann
Oncol 2005;16(3):403e10.
[18] Darai E, Teboul J, Fauconnier A, Scoazec JY, Beniﬂa J, Madelenat P. Manage-
ment and outcome of borderline ovarian tumors incidentally discovered at or
after laparoscopy. Acta Obstet Gynecol Scand 1998;77(4):451e7.
[19] Morris RT, Gershenson DM, Silva EG, Follen M, Morris MM, Wharton JT.
Outcome and reproductive function after conservative surgery for borderline
ovarian tumors. Obstet Gynecol 2000;95(4):541e7.
[20] Yinon Y, Beiner ME, Gotlieb WH, Korach Y, Perri T, Ben-Baruch G. Clinical
outcome of cystectomy compared with unilateral salpingo-oophorectomy as
fertility-sparing treatment of borderline ovarian tumors. Fertil Steril
2007;88(2):479e84.
[21] Prat J, de Nictolis M. Serous borderline tumors of the ovary: a long-term
follow-up study of 137 cases, including 18 with a micropapillary pattern
and 20 with microinvasion. Am J Surg Pathol 2002;26(9):1111e28.
[22] Longacre TA, McKenney JK, Tazelaar HD, Kempson RL, Hendrickson MR.
Ovarian serous tumors of low malignant potential (borderline tumors):
outcome-based study of 276 patients with long-term ( 5-year) follow-up.
Am J Surg Pathol 2005;29(6):707e23.
[23] Lim-Tan SK, Cajigas HE, Scully RE. Ovarian cystectomy for serous borderline
tumors: a follow-up study of 35 cases. Obstet Gynecol 1988;72:775e81.
[24] Park JY, Kim DY, Kim JH, Kim YM, Kim YT, Nam JH. Surgical management of
borderline ovarian tumors: the role of fertility-sparing surgery. Gynecol Oncol
2009;113(1):75e82.
[25] Boran N, Cil AP, Tulunay G, Ozturkoglu E, Koc S, Bulbul D, et al. Fertility and
recurrence results of conservative surgery for borderline ovarian tumors.
Gynecol Oncol 2005;97(3):845e51.
[26] Donnez J, Munschke A, Berliere M, Pirard C, Jadoul P, Smets M, et al. Safety of
conservative management and fertility outcome in women with borderline
tumors of the ovary. Fertil Steril 2003;79(5):1216e21.
[27] Rao GG, Skinner EN, Gehrig PA, Duska LR, Miller DS, Schorge JO. Fertility-
sparing surgery for ovarian low malignant potential tumors. Gynecol Oncol
2005;98(2):263e6.
[28] Trope CG, Kristensen G, Makar A. Surgery for borderline tumor of the ovary.
Semin Surg Oncol 2000;19:69e75.
[29] De Iaco P, Ferrero A, Rosati F, Melpignano M, Biglia N, Rolla M, et al. Behaviour
of ovarian tumors of low malignant potential treated with conservative sur-
gery. Eur J Surg Oncol 2009;35(6):643e8.
[30] Tamakoshi K, Kikkawa F, Nakashima N, Tamakoshi A, Kawai M, Furuhashi Y,
et al. Clinical behavior of borderline ovarian tumors: a study of 150 cases.
J Surg Oncol 1997;64:147e52.
[31] Camatte S, Morice P, Atallah D, Thoury A, Pautier P, Lhomme C, et al. Clinical
outcome after laparoscopic pure management of borderline ovarian tumors:
results of a series of 34 patients. Ann Oncol 2004;15(4):605e9.
[32] Morice P, Camatte S, El Hassan J, Patricia P, Duvillard P, Castaigne D. Clinical
outcomes and fertility after conservative treatment of ovarian borderline
tumors. Fertil Steril 2001;75(1):92e6.
[33] Makarewicz H, Olszewski J, Konefka T, Emerich J. [Pregnancy, labor and pu-
erperium in patients after surgery for ovarian tumors of borderline malig-
nancy]. Ginekol Pol 1998;69(12):1089e92.
[34] Vigano R, Petrone M, Pella F, Rabaiotti E, Marzi PD, Mangili G. Surgery in
advanced borderline tumors. Fertil Steril 2010;94(3):1163e5.
[35] Song T, Choi CH, Kim HJ, Lee W, Lee YY, Kim TJ, et al. Oncologic and repro-
ductive outcomes in patients with advanced-stage borderline ovarian tumors.
Eur J Obstet Gynecol Reprod Biol 2011;156(2):204e8.
[36] Kane A, Uzan C, Gouy S, Pautier P, Duvillard P, Morice P. Fertility results and
outcomes after pure laparoscopic management of advanced-stage serous
borderline tumors of the ovary. Fertil Steril 2010;94(7):2891e4.
[37] Defﬁeux X, Morice P, Camatte S, Fourchotte V, Duvillard P, Castaigne D. Re-
sults after laparoscopic management of serous borderline tumor of the ovary
with peritoneal implants. Gynecol Oncol 2005;97(1):84e9.
[38] Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The
Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised
studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/
oxfordhtm. [Accessed 29 Apr 2004].
[39] Swanton A, Bankhead CR, Kehoe S. Pregnancy rates after conservative treat-
ment for borderline ovarian tumours: a systematic review. Eur J Obstet
Gynecol Reprod Biol 2007;135(1):3e7.
[40] Trimble CL, Kosary C, Trimble EL. Long-term survival and patterns of care in
women with ovarian tumors of low malignant potential. Gynecol Oncol
2002;86(1):34e7.
[41] Song K, Kong BH. The problem of borderline ovarian tumors. Int J Gynaecol
Obstet 2013;40:288e309.
